Schiff income up
This article was originally published in The Tan Sheet
Executive SummaryThe Salt Lake City company attributes its fiscal 2010 first-quarter profitability to strong branded sales offsetting a decline in private-label volume. Schiff Nutrition International reported a 35.1 percent leap in net income to $4.4 million in the three months ended Aug. 31, along with net sales growth of 1.6 percent to $48.6 million. Net income per share was 15 cents in the quarter, compared to 11 cents in the year-ago period, Schiff said Sept. 17. The firm pared costs in the quarter, reducing selling and marketing expenses to $6.6 million from $8.1 million
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.